Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – England agrees funding for Gilead hepatitis C drug

[Reuters] – Health authorities in England have approved an 18.7 million pound ($31 million) investment to provide Gilead Sciences’ controversial new hepatitis C pill Sovaldi for seriously ill patients. Healthcare provider NHS England . . . → Read More: Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – England agrees funding for Gilead hepatitis C drug Similar Articles: Company Update (NASDAQ:GILD): Texas Medicaid holds off on proposed limits for Gilead hepatitis drug Company Update – Gilead Sciences Inc. (NASDAQ:GILD) – Mounting optimism for hepatitis C drug boosts Gilead to lead S&P 500 Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.